e-Therapeutics Pulls in £16.6 million to Pursue Network Pharmacology Drug Discovery
This article was originally published in The Pink Sheet Daily
Executive Summary
AIM-listed e-Therapeutics has raised £16.6 million in a placing to pursue the promise of network pharmacology as a new drug discovery process
You may also be interested in...
e-Therapeutics Explores Network Pharmacology For Drug Discovery, Moves First Of Its Drugs Into Clinical Studies
The U.K. company e-Therapeutics outlines its novel "network pharmacology" approach for discovery R&D, its product pipeline, and collaboration plans as it moves its first product, with potential in cancer, into Phase I studies.
France's Pharnext Attracts Business Leaders As Investors; Uses Network Pharmacology For New Low-Dose Combos
French industrialists invest in a Series B fundraising for Pharnext, attracted by its network pharmacology approach to neurological and other diseases.
France's Pharnext Attracts Business Leaders As Investors; Uses Network Pharmacology For New Low-Dose Combos
French industrialists invest in a Series B fundraising for Pharnext, attracted by its network pharmacology approach to neurological and other diseases.